Details
Stereochemistry | ACHIRAL |
Molecular Formula | C26H26ClN3 |
Molecular Weight | 415.958 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CN=CC(CN2CCC(CC2)=C3C4=C(CCC5=C3N=CC=C5)C=C(Cl)C=C4)=C1
InChI
InChIKey=WUZYKBABMWJHDL-UHFFFAOYSA-N
InChI=1S/C26H26ClN3/c1-18-13-19(16-28-15-18)17-30-11-8-20(9-12-30)25-24-7-6-23(27)14-22(24)5-4-21-3-2-10-29-26(21)25/h2-3,6-7,10,13-16H,4-5,8-9,11-12,17H2,1H3
Molecular Formula | C26H26ClN3 |
Molecular Weight | 415.958 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.tga.gov.au/auspar/auspar-rupatadineCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8996188 | https://www.ncbi.nlm.nih.gov/pubmed/27500993
Sources: https://www.tga.gov.au/auspar/auspar-rupatadine
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8996188 | https://www.ncbi.nlm.nih.gov/pubmed/27500993
Rupatadine is characterised as a non-sedating H1 anti-histamine and platelet-activating factor (PAF) receptor antagonist. Rupatadine is indicated for the treatment of allergic rhinitis and urticaria. Rupatadine is a safe and well tolerated drug in patients over 2 years old, with no central nervous system or cardiovascular effects and it can be taken with or without foods.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27500993 | https://www.tga.gov.au/auspar/auspar-rupatadine
Curator's Comment: Rupatadine poorly crosses the blood-brain barrier, however rupatidine fumarate displays psychomotor impairment activity only at the highest dose (80 mg), while therapeutically relevant lower doses (10 and 20 mg) were similar to placebo.
https://www.ncbi.nlm.nih.gov/pubmed/15539863
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | RUPAFIN Approved UseSymptomatic treatment of allergic rhinitis and urticaria Launch Date1.04129279E12 |
|||
Primary | RUPAFIN Approved UseSymptomatic treatment of allergic rhinitis and urticaria Launch Date1.04129279E12 |
PubMed
Title | Date | PubMed |
---|---|---|
A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. | 2004 |
|
Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. | 2005 |
|
The proarrhythmic antihistaminic drug terfenadine increases spontaneous calcium release in human atrial myocytes. | 2006 Dec 28 |
|
Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. | 2006 Jan |
|
Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. | 2006 Jan |
|
New antihistamines: a critical view. | 2006 Nov |
|
Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. | 2006 Oct |
|
Rupatadine: a review of its use in the management of allergic disorders. | 2007 |
|
Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. | 2007 Jul |
|
[Protective effect of rupatadine against oleic acid-induced acute lung injury in rabbits]. | 2007 Mar |
|
Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study. | 2007 May |
|
Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. | 2007 May |
|
Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. | 2007 May-Jun |
|
Rupatadine in allergic rhinitis and chronic urticaria. | 2008 Apr |
|
Antihistaminic effects of rupatadine and PKPD modelling. | 2008 Apr-Jun |
|
High performance liquid chromatography-tandem mass spectrometric determination of rupatadine in human plasma and its pharmacokinetics. | 2008 Aug 5 |
|
A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. | 2008 Jul |
|
[Torsades de pointes associated with rupatadine]. | 2008 Mar |
|
Herbex-kid Inhibits Immediate Hypersensitivity Reactions in Mice and Rats. | 2008 Sep |
|
Determination of rupatadine in pharmaceutical formulations by a validated stability-indicating MEKC method. | 2008 Sep |
|
Reduction of nasal volume after allergen-induced rhinitis in patients treated with rupatadine: a randomized, cross-over, double-blind, placebo-controlled study. | 2009 |
|
Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain. | 2009 |
|
Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines. | 2009 Aug 31 |
|
Rupatadine: pharmacological profile and its use in the treatment of allergic rhinitis. | 2009 Dec |
|
Paradoxical exacerbation of chronic urticaria by H1-antihistamines and montelukast. | 2009 Dec |
|
Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis. | 2009 Jun |
|
Heart rhythm disturbances associated with rupatadine: a case series from the Spanish and Portuguese pharmacovigilance systems. | 2009 May |
|
The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg. | 2009 Sep |
|
Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis. | 2009 Sep-Oct |
|
Structurally diverse metal coordination compounds, bearing imidodiphosphinate and diphosphinoamine ligands, as potential inhibitors of the platelet activating factor. | 2010 |
|
Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. | 2010 |
|
No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines. | 2010 Apr |
|
Rupatadine improves nasal symptoms, airflow and inflammation in patients with persistent allergic rhinitis: a pilot study. | 2010 Apr-Jun |
|
Rupatadine and levocetirizine for seasonal allergic rhinitis: a comparative study of efficacy and safety. | 2010 Aug |
|
Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males. | 2010 Dec |
|
Stereoselective synthesis of desloratadine derivatives as antagonist of histamine. | 2010 Feb 15 |
|
Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. | 2010 Jan |
|
Rupatadine and heart rhythm disturbances. | 2010 Jan |
|
Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study. | 2010 Jun |
|
[Rupatadine, oral Rupatall]. | 2010 Mar |
Sample Use Guides
Adults and adolescents (over 12 years of age): The recommended dose is 10 mg (one tablet) once a day, with or without food.
Paediatric patients: Rupatadine 10 mg Tablets is not recommended for use in children below age 12. In children aged 2 to 11 years, the administration of rupatadine 1 mg/ml oral solution is recommended.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24267366
platelet-activating factor stimulated a statistically significant release of histamine, interleukin-8, and tumor necrosis factor (0.001-0.1 μmol/L). Pretreatment with rupatadine (25 μmol/L) for 10 minutes inhibited this effect.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:38:48 UTC 2023
by
admin
on
Wed Jul 05 23:38:48 UTC 2023
|
Record UNII |
2AE8M83G3E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R06AX28
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
||
|
WHO-VATC |
QR06AX28
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
RUPATADINE
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
PRIMARY | |||
|
7443
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
PRIMARY | |||
|
DTXSID00166534
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
PRIMARY | |||
|
CHEMBL91397
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
PRIMARY | |||
|
DB11614
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
PRIMARY | |||
|
SUB10406MIG
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
PRIMARY | |||
|
C73055
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
PRIMARY | |||
|
2AE8M83G3E
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
PRIMARY | |||
|
133017
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
PRIMARY | |||
|
C103639
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
PRIMARY | |||
|
158876-82-5
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
PRIMARY | |||
|
100000084369
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
PRIMARY | |||
|
2413
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
PRIMARY | |||
|
M9700
Created by
admin on Wed Jul 05 23:38:48 UTC 2023 , Edited by admin on Wed Jul 05 23:38:48 UTC 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|